Dimensional Fund Advisors LP Buys 14,769 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Dimensional Fund Advisors LP boosted its stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 103.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,074 shares of the company’s stock after acquiring an additional 14,769 shares during the period. Dimensional Fund Advisors LP owned 0.07% of Prelude Therapeutics worth $111,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kennedy Capital Management LLC bought a new stake in shares of Prelude Therapeutics in the 1st quarter worth approximately $119,000. Massachusetts Financial Services Co. MA lifted its position in shares of Prelude Therapeutics by 2.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock valued at $1,990,000 after buying an additional 14,226 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Prelude Therapeutics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock valued at $4,821,000 after buying an additional 10,143 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Prelude Therapeutics by 42.7% during the 1st quarter. Acadian Asset Management LLC now owns 22,110 shares of the company’s stock worth $104,000 after acquiring an additional 6,615 shares during the period. 79.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PRLD has been the topic of several recent research reports. Barclays downgraded shares of Prelude Therapeutics from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a report on Thursday, June 20th. HC Wainwright raised shares of Prelude Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 19th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $7.00 price objective on shares of Prelude Therapeutics in a research note on Monday, September 16th.

Prelude Therapeutics Trading Down 1.5 %

Shares of Prelude Therapeutics stock opened at $1.91 on Wednesday. The company’s 50-day moving average price is $3.84 and its 200-day moving average price is $4.16. Prelude Therapeutics Incorporated has a 12-month low of $1.66 and a 12-month high of $6.80. The company has a market cap of $80.37 million, a price-to-earnings ratio of -1.02 and a beta of 1.48.

Prelude Therapeutics (NASDAQ:PRLD) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.46) EPS for the quarter, meeting the consensus estimate of ($0.46). On average, sell-side analysts predict that Prelude Therapeutics Incorporated will post -1.85 earnings per share for the current year.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.